- Numinus Wellness Inc. (NUMI) announced that its Neurology Centre of Toronto is now offering ketamine-assisted therapy
- The centre helps with conditions like epilepsy, concussion, brain injury, and functional neurological disorders
- The new service will be led by a psychologist and follows an existing protocol
- Numinus’ centre is also offering other psychedelic-assisted therapies through Health Canada’s Special Access Program
- Numinus Wellness Inc. (NUMI) is down 3.39 per cent, trading at $0.28 per share as of 2:42 p.m. ET
Numinus Wellness’s (NUMI) Neurology Centre in Toronto is now offering ketamine-assisted therapy for patients with neurologic conditions.
The company stated its new service will be led by a psychologist and follows Numinus’ existing protocol for ketamine-assisted therapy, which includes sessions for medical screening, medicine dosing and therapy for integration. The protocol will be modified to ensure it is appropriate for patients with neurological conditions.
Dr. Evan Lewis, Vice President of Psychedelic Neurology at Numinus, commented,
“Mental health challenges are commonly associated with neurologic diagnoses, and ketamine-assisted therapy is a promising tool that we now have available for our patients.”
The centre focuses on conditions like epilepsy, concussion, brain injury, and functional neurological disorders.
In addition to ketamine-assisted therapy, Numinus’ centre is expanding its capabilities to support other psychedelic-assisted therapies through Health Canada’s Special Access Program (SAP).
The SAP is a federal program for patients who need access to investigational medical treatments that are not yet available to the public, such as MDMA and psilocybin. A successful SAP application was recently completed by a Montreal Numinus physician to provide psilocybin-assisted therapy for depression.
Payton Nyquvest, CEO and founder of Numinus, added,
“Our patients often face complex challenges… By offering these additional services, we can help alleviate their distress and improve their quality of life.”
Numinus Wellness Inc. (NUMI) is down 3.39 per cent, trading at $0.28 per share as of 2:42 p.m. ET.
